顶流葛兰，重启限购

Core Viewpoint - Recent announcements from multiple high-performing funds under China Europe Fund indicate a trend of limiting large purchases to ensure stable fund operations and protect the interests of existing fund holders [1][3][15]. Fund Purchase Limitations - On August 9, China Europe Fund announced that starting from August 11, the China Europe Medical Innovation Fund would limit single-day purchases to 100,000 yuan per account [3][5]. - This is not the first instance; a similar limit was imposed on another medical fund managed by the same manager, Guo Lan, since January 2021 [1][2]. Fund Performance and Holdings - As of mid-2023, the China Europe Medical Innovation Fund had a total net asset value exceeding 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the portfolio, respectively [6][7]. - The top ten holdings of the fund include notable companies such as Sanofi Pharmaceutical and WuXi AppTec, with significant year-to-date price increases, including a nearly 400% rise for the largest holding, Sanofi Pharmaceutical [6][8]. Market Trends and Reactions - The recent surge in the innovative drug sector has led to substantial gains for the fund's holdings, with an average increase of over 100% for the top ten stocks this year [7][8]. - The fund's unit net value has also risen significantly, reaching 1.6874 yuan, compared to a low of below 0.9 yuan a year ago [9]. Broader Industry Context - The trend of limiting fund purchases is not isolated; approximately 50 actively managed equity funds have announced similar restrictions since July, reflecting a broader industry response to rapid inflows and the need to maintain investment strategy effectiveness [14][15]. - Industry experts suggest that these measures are aimed at controlling fund size to enhance investment efficiency and protect existing investors from potential losses due to market volatility [15][16].